Improved survival in ETP and near-ETP ALL using risk-adapted therapy based on MRD. As reported by Wood et al, patients with ETP and near-ETP ALL achieved 5-year event-free survival equivalent to not-ETP ALL using this approach. EFS, event-free survival; SD, standard deviation.